Form 4: Zoetis Executive Vice President Nicholas Ashton Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Executive Vice President Nicholas Ashton reports the acquisition of stock options and restricted stock units in Zoetis Inc.
Summary
- Nicholas Ashton, an Executive Vice President at Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the acquisition of 8,642 stock options with an exercise price of $156.64, vesting in three equal installments starting February 19, 2025, and expiring ten years from the grant date.
- Ashton also acquired 2,218 restricted stock units (RSUs), which will vest in three equal installments starting February 19, 2025.
- The RSUs represent a contingent right to receive one share of Zoetis Inc. common stock each.
- The filing also mentions existing holdings of stock options with exercise prices of $196.14 (4,289 options), $162.07 (4,304 options), and various grants from 2020-2022 (3,369 options).
- Existing holdings of 752 and 393 restricted stock units are also mentioned.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which are generally viewed neutrally to positively as they align management interests with shareholder value. The grants themselves are a positive sign of confidence in the executive's future contributions.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages continued service and commitment to the company's long-term success.
Future Outlook
The vesting schedules for the stock options and RSUs extend over the next three years, incentivizing continued service.
Industry Context
Stock option and RSU grants are a common practice in the pharmaceutical and animal health industries to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Zoetis' executive compensation practices, including the use of stock options and RSUs, are generally in line with industry standards for large pharmaceutical and animal health companies.
- Companies like Elanco and Merck Animal Health also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- Shareholders: The grants align executive interests with shareholder value.
- Employees: The grants can serve as a motivational tool for other employees.
Key Dates
| Date | Description |
|---|---|
| October 30, 2020 | 1,930 options granted at an exercise price of $158.55 per option |
| February 10, 2021 | 785 options granted at an exercise price of $160.62 per option |
| February 8, 2022 | 654 options granted at an exercise price of $201.30 per option |
| February 8, 2023 | One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| February 6, 2024 | One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| February 19, 2025 | Date of the latest transaction: grant of stock options and RSUs. |
Keywords
Form 4, Zoetis, Stock Options, Restricted Stock Units, Beneficial Ownership, Executive Compensation, Nicholas Ashton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.